Terumo (OTCMKTS:TRUMY – Get Free Report) released its quarterly earnings data on Friday. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13, Zacks reports. The business had revenue of $1.97 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Terumo had a net margin of 12.09% and a return on equity of 9.17%.
Terumo Price Performance
Shares of OTCMKTS TRUMY opened at $15.85 on Friday. The firm’s 50-day moving average price is $14.00 and its 200-day moving average price is $13.56. Terumo has a 1-year low of $12.08 and a 1-year high of $19.60. The firm has a market capitalization of $23.38 billion, a P/E ratio of 22.32 and a beta of 0.68. The company has a current ratio of 1.59, a quick ratio of 0.97 and a debt-to-equity ratio of 0.06.
Wall Street Analysts Forecast Growth
Separately, Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Terumo presently has an average rating of “Buy”.
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
Featured Stories
- Five stocks we like better than Terumo
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
